SmartBreast acquires molecular breast tech from Dilon

2021 01 04 20 06 5281 2021 01 04 Dilon Smartbreast 20210104205854

Private breast cancer screening firm SmartBreast has acquired molecular breast imaging technologies and patents from developer Dilon Diagnostics.

The acquisition includes the Dilon 6800 molecular breast imaging scanner, the GammaLoc MBI-guided biopsy device, and a variable-angle slant-hole (VASH) collimator. It also includes tomographic software that uses the VASH collimator for molecular breast tomography as well as acquisition and analysis software.

The Dilon D6800 MBI scanner. Image courtesy of SmartBreast.The Dilon D6800 MBI scanner. Image courtesy of SmartBreast.

In addition, SmartBreast acquired all inventory, designs, manufacturing tools, and multiple registered trademarks and patents. The acquisition also extends to two 510(k) clearances from the U.S. Food and Drug Administration as well as regulatory registrations in other countries.

SmartBreast made the acquisition for an undisclosed amount. The company also announced it is beginning a $5 million seed financing round.

Page 1 of 568
Next Page